[1]陈 敏,沈亚卉.非小细胞肺癌组织中CLDN10 和CSPG4 水平表达与临床病理特征及预后的关系研究[J].现代检验医学杂志,2024,39(02):46-50+74.[doi:10.3969/j.issn.1671-7414.2024.02.009]
　CHEN Min,SHEN Yahui.Study on the Relationship between CLDN10 and CSPG4 Levels Expression of Tissue and Clinicopathological Characteristics and Prognosis in Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2024,39(02):46-50+74.[doi:10.3969/j.issn.1671-7414.2024.02.009]
点击复制

非小细胞肺癌组织中CLDN10 和CSPG4 水平表达与临床病理特征及预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年02期
页码:
46-50+74
栏目:
论著
出版日期:
2024-03-15

文章信息/Info

Title:
Study on the Relationship between CLDN10 and CSPG4 Levels Expression of Tissue and Clinicopathological Characteristics and Prognosis in Non-small Cell Lung Cancer
文章编号:
1671-7414（2024）02-046-06
作者:
陈 敏; 沈亚卉
（南京医科大学附属泰州市人民医院呼吸与危重症医学科，江苏泰州 225300）
Author(s):
CHEN Min;  SHEN Yahui
（Department of Respiratory and Critical Care Medicine, Taizhou People’s Hospital, Nanjing Medical University, Jiangsu Taizhou 225300, China）
关键词:
非小细胞肺癌; 紧密连接蛋白10; 硫酸软骨素蛋白聚糖4
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.02.009
文献标志码:
A
摘要:
目的　探讨非小细胞肺癌（non-small cell lung cancer，NSCLC） 组织中紧密连接蛋白10（claudin 10，CLDN10）和硫酸软骨素蛋白聚糖4（chondroitin sulfate proteoglycan 4，CSPG4）表达与临床病理特征和预后的关系。方法　随机选取2017 年1 月~2018 年4 月于南京医科大学附属泰州市人民医院进行手术的136 例NSCLC 患者为研究对象，并根据随访结局（生存或死亡）分为生存组（n=63）和死亡组（n=69）。收集136 例患者于手术过程中切除的癌组织及癌旁组织标本；实时荧光定量PCR（real-time fluorescence quantitative PCR，RT-qPCR）检测癌组织及癌旁组织CLDN10 和CSPG4 表达水平，并分别以NSCLC 患者癌组织中CLDN10 和CSPG4 表达水平的平均数为界限，分为CLDN10 高表达组（n=66），CLDN10 低表达组（n=70）和CSPG4 高表达组（n=71），CSPG4 低表达组（n=65）；采用多因素COX 回归分析确定NSCLC 患者预后的影响因素；采用Kaplan-Meier 生存曲线分析NSCLC 患者CLDN10和CSPG4 表达水平与其预后的关系。结果　NSCLC 组织中CLDN10 表达水平（0.96 ± 0.25）低于癌旁组织（1.73 ±0.42），CSPG4 表达水平（1.80 ± 0.46）高于癌旁组织（1.04 ± 0.27），差异有统计学意义（t=18.372，16.617，均P＜ 0.05）。与生存组比较，死亡组低未分化占比、淋巴结转移占比及癌组织中CSPG4 表达水平较高，CLDN10 表达水平较低，差异具有统计学意义（t/χ2=8.463，7.423，11.696，6.426，均P ＜ 0.05）。CLDN10 高表达组五年存活率（58.46%）高于低表达组（37.31%），CSPG4 低表达组患者五年存活率（55.56%）高于高表达组（40.58%），差异有统计学意义（χ2=7.848，4.018，均P ＜ 0.05）。多因素COX 分析结果显示，CLDN10 低表达、CSPG4 高表达、低分化程度、淋巴结转移是NSCLC 患者预后的危险因素（HR=1.362，1.368，1.335，1.314，均P ＜ 0.05）。结论　NSCLC 患者癌组织中CLDN10 表达水平较低，CSPG4 水平较高，且与NSCLC 发展和预后密切相关。
Abstract:
Objective　To investigate the relationship between the expression of claudin 10 (CLDN10) and chondroitin sulfate proteoglycan 4 (CSPG4) of tissue and clinicopathologic characteristics and prognosis in non-small cell lung cancer (NSCLC). Methods　A total of 136 NSCLC patients who underwent surgery in Taizhou People’s Hospital, Nanjing Medical University from January 2017 to April 2018 were randomly selected as the study subjects, and these subjects were grouped into survival group (n=63) and death group (n=69) based on follow-up outcomes (survival or death). Specimens of cancer tissue and adjacent tissues excised during surgery were collected from 136 patients. Real-time fluorescence quantitative PCR (RT-qPCR) was applied to detect the expression levels of CLDN10 and CSPG4 in cancer tissue and adjacent tissues. Based on the average expression levels of CLDN10 and CSPG4 in cancer tissues of NSCLC patients, they were grouped into CLDN10 high expression group (n=66), CLDN10 low expression group (n=70) and CSPG4 high expression group (n=71), CSPG4 low expression group (n=65). Multivariate COX regression analysis was used to determine the prognostic factors of NSCLC patients. Kaplan-Meier survival curve was applied to analyze the relationship between the expression levels of CLDN10 and CSPG4 in NSCLC patients and their prognosis. Results　The expression level of CLDN10 (0.96 ± 0.25) in NSCLC tissues was lower than that in adjacent tissue (1.73 ± 0.42), and the expression level of CSPG4 in NSCLC tissues (1.80 ± 0.46) was higher than that in adjacent tissues (1.04 ± 0.27), with statistical significance (t=18.372, 16.617, all P < 0.05). Compared with the survival group, the proportion of low undifferentiated, lymph node metastasis and CSPG4 expression of cancer tissues in the death group were higher, and the CLDN10 expression level of cancer tissues in the death group was lower, with statistical significance (t/χ2=8.463, 7.423, 11.696, 6.426, all P < 0.05). The five-year survival rate of the high expression group of CLDN10 (58.46%) was higher than that of the low expression group (37.31%), and the five-year survival rate of the low expression group of CSPG4 (55.56%) was higher than that of the high expression group (40.58%), and the differences were statistically significant (χ2=7.848, 4.018, all P < 0.05). Multivariate COX analysis results showed that low expression of CLDN10, high expression of CSPG4, low differentiation degree, and lymph node metastasis were all risk factors affecting the prognosis of NSCLC patients (HR=1.362, 1.368, 1.335, 1.314, all P<0.05). Conclusion　The expression level of CLDN10 was low and CSPG4 was high in cancer tissues of NSCLC patients, which was closely related to the development and prognosis of NSCLC.

参考文献/References:

[1] LIU Junhui, TIAN Yubin, YI Lei, et al. High KIF11 expression is associated with poor outcome of NSCLC[J]. Tumori, 2022, 108(1): 40-46.
[2] SRIVASTAVA S, MOHANTY A, NAM A, et al. Chemokines and NSCLC: emerging role in prognosis,heterogeneity, and therapeutics[J]. Seminars in Cancer Biology, 2022, 86(Pt 2): 233-246.
[3] GIRARD N, BASSE C. EGFR-mutant NSCLC:monitoring the molecular evolution of tumors in 2022[J]. Expert Review of Anticancer Therapy, 2022,22(10): 1115-1125.
[4] DAS D, WANG Jingbing, HONG Jian. Next-generation kinase inhibitors targeting specific biomarkers in nonsmall cell lung cancer (NSCLC): A recent overview[J].Chem Med Chem, 2021, 16(16): 2459-2479.
[5] 张涛元, 丁雪梅, 李俏, 等. 人非小细胞肺癌组织中转录因子E2F 家族表达与临床病理特征及预后的相关性分析[J]. 现代检验医学杂志, 2022, 37（4）：87-91. ZHANG Taoyuan, DING Xuemei, LI Qiao, et al. Correlation analysis of transcription factor E2F family expression with clinicopathological features and prognosis in human non-small cell lung cancer[J].Journal of Modern Laboratory Medicine, 2022, 37(4):87-91.
[6] 陈琪, 何明旭, 韩丽萍. 紧密连接蛋白在非小细胞肺癌中的研究进展[J]. 临床荟萃, 2022, 37（6）：564-567. CHEN Qi, HE Mingxu, HAN Liping. Research progress of tight junction protein in non-small cell lung cancer[J]. Clinical Focus, 2022, 37(6): 564-567.
[7] EGAN C E, STEFANOVA D, AHMED A, et al. CSPG4 is a potential therapeutic target in anaplastic thyroid cancer[J]. Thyroid, 2021, 31(10): 1481-1493.
[8] 中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018 版)[J].中华肿瘤杂志, 2018, 40（12）：935-964. Chinese Medical Association, Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Chinese medical association guidelines for clinical diagnosis and treatment of lung cancer(Edition 2018)[J]. Chinese Journal of Oncology, 2018, 40(12): 935-964.
[9] 李雪, 朱亚芯, 雷立锋, 等. 非小细胞肺癌组织中miR-371-5p, miR-452, miR-5100, LZTS1 表达水平及临床意义[J]. 实用癌症杂志, 2022, 37（4）：564-567. LI Xue, ZHU Yaxin, LEI Lifeng, et al. The expression levels of miR-371-5p, miR-452, miR-5100, LZTS1 in non-small cell lung cancer tissues and their clinical significance[J]. Practical Journal of Cancer, 2022,37(4): 564-567.
[10] CHEN Peixin, LIU Yunhuan, WEN Yaokai, et al. Non-small cell lung cancer in China[J]. Cancer Communications (London, England), 2022, 42(10):937-970.
[11] LE Xiuning, NILSSON M, GOLDMAN J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC[J]. Journal of Thoracic Oncology, 2021, 16(2): 205-215.
[12] EVISON M, ASTRAZENECA U L. The current treatment landscape in the UK for stage III NSCLC[J].British Journal of Cancer, 2020, 123(Suppl 1): 3-9.
[13] 宗曾艳. 非编码RNA 及DNA 甲基化在鼻咽癌中的作用机制研究[D]. 安徽: 安徽理工大学, 2021:1-53. ZONG Zengyan. Analysis on the mechanism of noncoding RNA and DNA methylation in nasopharyngeal carcinoma[D]. Anhui: Anhui University of Science & Technology, 2021: 1-53.
[14] YANG Wuping, ZHANG Kenan, ZHANG Zedan,et al. Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP50 and causing mitochondrial dysfunction[J]. International Journal of Biological Sciences, 2022, 18(6): 2329-2344.
[15] XIANG Zhaolan, ZHONG Cheng, CHANG Aoshuang,et al. Immune-related key gene CLDN10 correlates with lymph node metastasis but predicts favorable prognosis in papillary thyroid carcinoma[J]. Aging(Albany NY),2020, 12(3): 2825-2839.
[16] 徐争光, 李灿楦, 李晓, 等. 基于数据挖掘分析CLDN10 基因在肾透明细胞癌的表达及临床意义[J].海南医学, 2021, 32(20): 2589-2596. XU Zhengguang, LI Canxuan, LI Xiao, et al. Analysis of CLDN10 gene expression and clinical significance in clear cell renal cell carcinoma based on data mining[J].Hainan Medical Journal, 2021, 32(20): 2589-2596.
[17] 袁刚军, 韩娜, 谭星亮, 等. 肿瘤微环境中M2 巨噬细胞调控CLDN10 通路促进膀胱癌细胞的上皮-间质转化[J]. 第三军医大学学报, 2021, 43(23): 2525-2531. YUAN Gangjun, HAN Na, TAN Xingliang, et al. M2 macrophages promotes bladder cancer EMT through CLDN10 involved signaling pathway in tumor microenvironment[ J]. Journal of Third Military Medical University, 2021, 43(23): 2525-2531.
[18] ZHUANG Xinguo, JI Wenxiao, FANG Ziqian, et al. Claudin-10 in the blood brain barrier function of cerebral endothelial cells and transendothelial invasion of breast cancer cells[J]. Anticancer Research, 2023,43(9): 3923-3934.
[19] ZHANG Hongyu, WU Zhenyu, HU Deyu, et al. Immunotherapeutic targeting of NG2/CSPG4 in solid organ cancers[J]. Vaccines, 2022, 10(7): 1023.
[20] 李军彦, 陈文超, 李中辉, 等. 胰腺导管腺癌中PTK7, CSPG4 表达及其临床意义[J]. 实用癌症杂志,2022, 37(6): 880-883. LI Junyan, CHEN Wenchao, LI Zhonghui, et al. Expression and clinical significance of PTK7 and CSPG4 in pancreatic ductal adenocarcinoma[J].Practical Journal of Cancer, 2022, 37(6): 880-883.
[21] 谢奇, 樊鑫梅, 韩永红, 等. Lnc-NEAT1 通过miR-29c-3p/CSPG4 信号轴调节黑色素瘤B16 细胞的增殖、迁移和侵袭[J]. 南京医科大学学报(自然科学版), 2023, 43（4）：492-501. XIE Qi, FAN Xinmei, HAN Yonghong, et al. Lnc-NEAT1 regulates the proliferation, migration and invasion of melanoma B16 cells through the miR-29c-3p/CSPG4 signaling axis[J]. Journal of Nanjing Medicial University (Natural Sciences), 2023, 43(4):492-501.
[22] 张玲玲, 张小霞, 於潇潇, 等. 非小细胞肺癌患者血浆miR-520f, miR-143-3p 表达与病理特征和预后的相关性研究[J]. 现代检验医学杂志, 2022, 37（3）：69-72, 78. ZHANG Lingling, ZHANG Xiaoxia, YU Xiaoxiao, et al. Correlation study on plasma miR-520f and miR-143-3p expression with pathological features and prognosis in patients with non-small cell lung cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 69-72, 78.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(02):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(02):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(02):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(02):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(02):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(02):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
作者简介：陈敏（1990-），女，硕士研究生，主治医师，研究方向：呼吸系统疾病，E-mail：ch3371f@163.com。
通讯作者：沈亚卉（1985-），女，博士研究生，副主任医师，研究方向：呼吸系统疾病基础与临床研究，E-mail：shenyahui@njmu.edu.cn。
更新日期/Last Update: 2024-03-15